1 / 15

Lancet 373:1765-72, 2009

Lancet 373:1765-72, 2009. Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment. Kay et al, Lancet 373:1765-72, 2009.

sakura
Download Presentation

Lancet 373:1765-72, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lancet 373:1765-72, 2009

  2. Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment Kay et al, Lancet 373:1765-72, 2009

  3. Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment Kay et al, Lancet 373:1765-72, 2009

  4. Event Rates of Cardiovascular Outcomes of Intensive-Lowering versus Standard Treatments Kay et al, Lancet 373:1765-72, 2009

  5. Probability of events of non-fatal myocardial infarction with intensive glucose-lowering vs. standard treatment Ray et al, Lancet 2009; 373: 1765–72

  6. Probability of events of coronary heart disease with intensive glucose-lowering vs. standard treatment

  7. Probability of events of stroke with intensive glucose-lowering versus standard treatment Ray et al, Lancet 2009; 373: 1765–72

  8. Probability of events of all-cause mortality with intensive glucose-lowering versus standard treatment Ray et al, Lancet 2009; 373: 1765–72

  9. Annals Internal Medicine 2009; 151: 394-403

  10. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and PAD UKPDS 34 UKPDS 34 ACCORD ADVANCE VADT Kelly et al, Ann Inter Med 2009; 151: 394-403

  11. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and PAD Kelly et al, Ann Inter Med 2009; 151: 394-403

  12. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of severe hypoglycemia Kelly et al, Ann Inter Med 2009; 151: 394-403

  13. Summary of Meta-Analysis • These 2 meta-analysis found that, compared with conventional control, intensive glucose control reduce the risk for cardiovascular disease (mostly nonfatal myocardial infarction) but not for cardiovascular death or all-cause mortality, and increased risk for severe hypoglycemia. • Early trials suggested possible decreased risk for death with intensive control, whereas some more recent trials suggested possible increased risk for death with more stringent control.

More Related